{"product_id":"icad-vrio-analysis","title":"iCAD, Inc. (ICAD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs iCAD, Inc. (ICAD) truly built for lasting success? This VRIO analysis rigorously tests the core of their business - its Value, Rarity, Inimitability, and Organization - to uncover whether they possess a sustainable competitive advantage. Dive in now to see the definitive verdict on what truly sets iCAD, Inc. (ICAD) apart from the competition and where their future strength lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 1. Proprietary AI Algorithms \u0026amp; Training Data Set\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of iCAD, Inc.’s value proposition - the proprietary AI algorithms and the massive, clinically-validated data set they run on. This isn't just software; it’s a competitive moat built over years of development and data aggregation. The immediate takeaway is that this combination is currently a \u003cstrong\u003esustained competitive advantage\u003c\/strong\u003e, provided the integration with RadNet’s DeepHealth unit continues to feed the beast.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Clinical Performance and Financial Impact\u003c\/h3\u003e\n\u003cp\u003eThe value here is direct: better patient care translates to market adoption and revenue. The ProFound Detection Version 4.0 algorithm, for instance, showed a \u003cstrong\u003e6.3%\u003c\/strong\u003e improved area under the receiver operating characteristic curve (AUC) over its prior iteration, which is a precise measure of diagnostic improvement. More concretely, this translates to a \u003cstrong\u003e22%\u003c\/strong\u003e overall improvement in detecting the most challenging and aggressive cancer subtypes. For example, detection in dense breast tissue improved by \u003cstrong\u003e50%\u003c\/strong\u003e. This clinical superiority directly supports the shift to a subscription model, evidenced by iCAD’s Total Annual Recurring Revenue (TARR) reaching \u003cstrong\u003e$10.7 million\u003c\/strong\u003e in the first quarter of 2025, with a Gross Profit Margin of \u003cstrong\u003e86%\u003c\/strong\u003e in that same period. That margin tells you the market values this intellectual property highly.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Scale and Diversity of Data\u003c\/h3\u003e\n\u003cp\u003eRarity hinges on the sheer volume and quality of the training data. While the exact number of global locations used for training isn't public, we know iCAD’s AI portfolio was deployed in over \u003cstrong\u003e50 countries\u003c\/strong\u003e before the acquisition, suggesting a broad, diverse patient population fed into the models. This scale is rare; general market data suggests that for top-tier vision models, datasets often need to be in the millions of data points to achieve robustness. The diversity - capturing everything from dense tissue cases to rare invasive lobular cancers - is what makes the model generalize well. It’s not just about the number of images, but the types of images.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: The Cost of Replication\u003c\/h3\u003e\n\u003cp\u003eImitability is high because competitors face a massive hurdle: time and clinical validation. Replicating the volume, diversity, and quality of historical, clinically-validated training data is incredibly time-consuming and expensive. You can buy an algorithm, but you can’t buy two decades of retrospective patient outcomes needed to train it to the level of ProFound Detection V4.0. The fact that the acquisition by RadNet, completed on \u003cstrong\u003eJuly 17, 2025\u003c\/strong\u003e, was valued at approximately \u003cstrong\u003e$103 million\u003c\/strong\u003e reflects the market’s assessment of this inimitability premium. It’s a high barrier to entry, plain and simple.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Integration for Future Growth\u003c\/h3\u003e\n\u003cp\u003eOrganization assesses whether iCAD is structured to exploit this resource. The integration into RadNet’s \u003cstrong\u003eDeepHealth\u003c\/strong\u003e portfolio is the key organizational move here. DeepHealth expects the combined installed base of over \u003cstrong\u003e1,500\u003c\/strong\u003e healthcare provider locations worldwide to allow them to scale their work to over \u003cstrong\u003e10 million\u003c\/strong\u003e mammograms annually. This structure provides the necessary operational scale and a continuous stream of new, real-world data to refine the algorithms further, moving the advantage from temporary to sustained. Here’s the quick math: more data feeds better AI, which drives more adoption, which generates more data.\u003c\/p\u003e\n\n\u003cp\u003eThe VRIO assessment for this core asset looks like this:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Temporary Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (Costly to Imitate)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Exploited)\u003c\/td\u003e\n\u003ctd\u003eYes (via RadNet\/DeepHealth)\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the speed of competitive response; if a major competitor like GE HealthCare or Siemens Healthineers can secure a massive, exclusive data partnership quickly, this advantage could erode faster than expected. Still, the historical data advantage is sticky.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDrive superior detection accuracy (e.g., \u003cstrong\u003e6.3%\u003c\/strong\u003e AUC improvement).\u003c\/li\u003e\n\u003cli\u003eImprove detection of aggressive cancers by \u003cstrong\u003e22%\u003c\/strong\u003e overall.\u003c\/li\u003e\n\u003cli\u003eLeverage TARR growth to \u003cstrong\u003e$10.7 million\u003c\/strong\u003e (Q1 2025).\u003c\/li\u003e\n\u003cli\u003eBenefit from \u003cstrong\u003e86%\u003c\/strong\u003e Q1 2025 Gross Margin.\u003c\/li\u003e\n\u003cli\u003eAccess to data streams via \u003cstrong\u003e1,500+\u003c\/strong\u003e provider locations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 2. Regulatory Clearances (FDA\/CE Mark)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e FDA clearance for key products like ProFound Detection Version 4.0 allows immediate market access and use in the crucial U.S. market. This clearance, granted on November 12, 2024, enables the deployment of an AI solution with a 6.3% improved Area Under the ROC Curve (AUC) over the prior version.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While competitors have clearances, iCAD’s first-mover FDA clearance for AI in DBT in 2016 provides a legacy advantage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can pursue clearances, but the time and cost associated with the multi-year regulatory process act as a hurdle. The development leading to Version 4.0 involved training on advanced deep learning convolutional neural networks (CNNs) to achieve specific performance metrics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The established regulatory affairs function, now bolstered by the transformational agreement with RadNet (transaction value approximately $103 million), ensures ongoing compliance and expansion of clearances globally.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Regulatory hurdles slow down new entrants, but a sustained advantage requires continuous product innovation to maintain market leadership post-clearance. The company reported $17.2 million in cash as of December 31, 2024, supporting ongoing R\u0026amp;D and regulatory pursuits.\u003c\/p\u003e\n\n\u003cp\u003eThe regulatory status of iCAD's core ProFound Breast Health Suite products demonstrates breadth across key regulatory bodies:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eFDA Status\u003c\/td\u003e\n\u003ctd\u003eCE Mark Status\u003c\/td\u003e\n\u003ctd\u003eHealth Canada Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProFound Detection (v4.0)\u003c\/td\u003e\n\u003ctd\u003eCleared (Nov 2024)\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for v4.0 in latest search\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for v4.0 in latest search\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProFound AI\u003c\/td\u003e\n\u003ctd\u003eCleared\u003c\/td\u003e\n\u003ctd\u003eCleared\u003c\/td\u003e\n\u003ctd\u003eLicensed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProFound Risk\u003c\/td\u003e\n\u003ctd\u003eInvestigational Use Only (US)\u003c\/td\u003e\n\u003ctd\u003eCE Marked (MDD)\u003c\/td\u003e\n\u003ctd\u003eLicensed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePowerLook Density Assessment\u003c\/td\u003e\n\u003ctd\u003eCleared\u003c\/td\u003e\n\u003ctd\u003eCleared\u003c\/td\u003e\n\u003ctd\u003eLicensed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe performance gains validated by the ProFound Detection Version 4.0 FDA clearance, compared to the previous version 3, include specific quantitative improvements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOverall improvement in detecting challenging\/aggressive cancer subtypes: \u003cstrong\u003e22%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImprovement in identifying cancers within dense breast tissue: \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImprovement in identifying invasive lobular cancers: \u003cstrong\u003e60%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImprovement in detecting invasive cancers: \u003cstrong\u003e21%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImprovement in identifying cancers smaller than 1 cm: \u003cstrong\u003e38%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReduction in false positive marks related to non-vascular calcifications: \u003cstrong\u003e51%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe successful clearance of Version 4.0 supports the company's financial transition, as Q4 2024 revenue reached \u003cstrong\u003e$5.4 million\u003c\/strong\u003e, a \u003cstrong\u003e14%\u003c\/strong\u003e increase year-over-year, with a Gross Profit Margin of \u003cstrong\u003e86%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 3. ProFound Breast Health Suite Product Line\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ProFound Breast Health Suite provides a comprehensive, integrated platform encompassing Detection, Density, and Risk assessment, addressing multiple clinical needs within a single commercial offering, which simplifies procurement for providers.\u003c\/p\u003e\n\u003cp\u003eThe value proposition is supported by clinical and efficiency metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProFound AI for DBT improved radiologist sensitivity by \u003cstrong\u003e8%\u003c\/strong\u003e and reduced unnecessary patient recall rates by \u003cstrong\u003e7.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRadiologists using ProFound AI experienced a 52.7% reduction in reading time for 3D mammography datasets, effectively halving the time.\u003c\/li\u003e\n\u003cli\u003eThe ProFound Risk solution offers up to \u003cstrong\u003e2.4x\u003c\/strong\u003e more accuracy than traditional lifetime risk models.\u003c\/li\u003e\n\u003cli\u003eKettering Health reported increasing patient volume by \u003cstrong\u003e15%\u003c\/strong\u003e without adding additional staff after implementation.\u003c\/li\u003e\n\u003cli\u003eOne site reported a decrease in interpretation times by an average of about \u003cstrong\u003e30 seconds\u003c\/strong\u003e per case.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While competitors offer Computer-Aided Detection (CAD) solutions, iCAD's specific, clinically proven combination across detection, density assessment, and short-term risk evaluation within one integrated suite is less common in the market.\u003c\/p\u003e\n\u003cp\u003eThe scale of adoption indicates market presence:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProFound is available in over \u003cstrong\u003e50 countries\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eiCAD estimates reading more than \u003cstrong\u003e40 million mammograms worldwide\u003c\/strong\u003e in the last five years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can develop individual modules for detection or risk, but replicating the seamless integration, established workflow compatibility, and consistent, proven performance across the entire suite requires significant time and investment in clinical validation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The product suite forms the core of the commercial strategy, evidenced by the focus on transitioning to a Software as a Service (SaaS) model to enhance usability and revenue predictability.\u003c\/p\u003e\n\u003cp\u003eFinancial metrics reflecting organizational focus on recurring revenue:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Annual Recurring Revenue (ARR) reached \u003cstrong\u003e$10.7 million\u003c\/strong\u003e as of Q1 2025, an \u003cstrong\u003e18%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eTotal ARR was \u003cstrong\u003e$9.8 million\u003c\/strong\u003e for the full year 2024, representing an \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eIn Q1 2025, \u003cstrong\u003e19\u003c\/strong\u003e new ProFound Cloud deals were closed.\u003c\/li\u003e\n\u003cli\u003eIn the full year 2024, \u003cstrong\u003e382\u003c\/strong\u003e total deals were closed, with \u003cstrong\u003e42\u003c\/strong\u003e being ProFound Cloud deals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company maintained a high Gross Profit Margin of \u003cstrong\u003e86%\u003c\/strong\u003e in Q1 2025, driven by higher-margin cloud revenues.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The current integrated nature and proven clinical outcomes provide a current advantage, but the industry trend is toward comprehensive platforms, suggesting competitors are actively working to build or acquire similar integrated capabilities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eReduces reading time by \u003cstrong\u003e52.7%\u003c\/strong\u003e; Risk model is up to \u003cstrong\u003e2.4x\u003c\/strong\u003e more accurate; Increased patient volume by \u003cstrong\u003e15%\u003c\/strong\u003e at one site.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eAvailable in over \u003cstrong\u003e50 countries\u003c\/strong\u003e; Over \u003cstrong\u003e40 million\u003c\/strong\u003e mammograms read in the last five years.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSeamless integration and proven performance across detection, density, and risk are difficult to replicate quickly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eCore commercial offering; ARR reached \u003cstrong\u003e$10.7 million\u003c\/strong\u003e in Q1 2025 (up \u003cstrong\u003e18%\u003c\/strong\u003e YoY); Gross Margin \u003cstrong\u003e86%\u003c\/strong\u003e in Q1 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eIntegrated suite is valuable now, but competitors are actively building comprehensive platforms.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 4. Annual Recurring Revenue (ARR) Base\u003c\/h2\u003e\n\u003cp\u003eThe Annual Recurring Revenue (ARR) base is a critical component of the VRIO framework, reflecting the shift towards a more stable, predictable revenue model, which is highly valued by investors and supports sustained investment in research and development.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides predictable revenue streams, which is crucial for valuation and funding R\u0026amp;D. Q1 2025 Total ARR was reported at \u003cstrong\u003e$10.7 million\u003c\/strong\u003e, up \u003cstrong\u003e18%\u003c\/strong\u003e Year-over-Year (YoY). This recurring revenue stream is a key indicator of successful adoption of the company's cloud-based solutions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While the transition to a Software as a Service (SaaS) model is becoming more common in MedTech, achieving a substantial and growing ARR base in this sector is not universal, making a growing ARR base a signal of successful SaaS transition adoption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can initiate a shift to SaaS offerings; however, establishing an ARR base of \u003cstrong\u003e$10.7 million\u003c\/strong\u003e requires significant, sustained sales execution and customer onboarding over multiple fiscal periods.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The organization is demonstrating successful execution of its recurring revenue strategy, evidenced by the consistent addition of cloud-based contracts.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Predictable revenue derived from ARR is a key differentiator for investors, supporting long-term strategic planning and capital allocation decisions.\u003c\/p\u003e\n\n\u003cp\u003eThe momentum in the recurring revenue segment can be further detailed by comparing recent quarterly performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal ARR reached \u003cstrong\u003e$10.7 million\u003c\/strong\u003e in Q1 2025, representing an \u003cstrong\u003e18%\u003c\/strong\u003e YoY increase.\u003c\/li\u003e\n\u003cli\u003eThe number of new cloud deals closed in Q1 2025 was \u003cstrong\u003e19\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Gross Profit Margin improved to \u003cstrong\u003e86%\u003c\/strong\u003e, up from \u003cstrong\u003e83%\u003c\/strong\u003e in Q1 2024, driven by higher-margin cloud revenues.\u003c\/li\u003e\n\u003cli\u003eOperating expenses were reduced by \u003cstrong\u003e4%\u003c\/strong\u003e in Q1 2025 compared to Q1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ4 2024 (Preliminary)\u003c\/th\u003e\n\u003cth\u003eQ1 2025 (Actual)\u003c\/th\u003e\n\u003cth\u003eYoY Change (Q1 vs Q1 Prior Year)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal ARR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+18%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Deals Closed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e106\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProFound Cloud Deals Closed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately flat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease from 83%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organization's focus on cloud deals, with \u003cstrong\u003e19\u003c\/strong\u003e new cloud deals in Q1 2025, demonstrates a commitment to scaling the recurring revenue base, which is a key indicator of management's successful execution of the SaaS transition strategy.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 5. Established Global Distribution Network\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eAllows iCAD to market products in over \u003cstrong\u003e50\u003c\/strong\u003e countries through direct sales, OEM partners, distributors, and resellers, expanding reach beyond the US. The company's full year \u003cstrong\u003e2024\u003c\/strong\u003e total revenue was approximately \u003cstrong\u003e$19.6 million\u003c\/strong\u003e, supported by this network.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. While many med-tech firms have distribution, iCAD’s established network in international markets for this specific niche is valuable. The company secured new distribution agreements in South Africa, Portugal, and the UK during \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. Building deep, trusted relationships with international distributors is a slow, relationship-based process. The network includes \u003cstrong\u003e17\u003c\/strong\u003e strategic medical equipment distributors across \u003cstrong\u003e8\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eGood. The network was in place before the acquisition, and RadNet’s scale will likely enhance its leverage. The US direct sales force consisted of \u003cstrong\u003e47\u003c\/strong\u003e representatives as of \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. While hard to copy overnight, a larger entity like RadNet could potentially integrate or replace parts of this network if synergies aren't realized. The Annual Recurring Revenue (ARR) for the full year \u003cstrong\u003e2024\u003c\/strong\u003e was \u003cstrong\u003e$9.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe global distribution structure is segmented as follows:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegion\u003c\/td\u003e\n\u003ctd\u003eNumber of Distribution Partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia-Pacific\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiddle East\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatin America\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe established channels for market penetration include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDirect Sales Force (\u003cstrong\u003e47\u003c\/strong\u003e representatives in the US as of \u003cstrong\u003e2024\u003c\/strong\u003e)\u003c\/li\u003e\n\u003cli\u003eOEM Partners (e.g., General Electric)\u003c\/li\u003e\n\u003cli\u003eDistributors (\u003cstrong\u003e17\u003c\/strong\u003e strategic partners globally)\u003c\/li\u003e\n\u003cli\u003eResellers\u003c\/li\u003e\n\u003cli\u003eOnline Sales Platform (generated \u003cstrong\u003e$4.2 million\u003c\/strong\u003e in \u003cstrong\u003e2023\u003c\/strong\u003e)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 6. Pioneering Market Position in AI for DBT\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Being the first to introduce an FDA-cleared AI solution for Digital Breast Tomosynthesis (DBT) in 2016 establishes a strong brand association with innovation in the field. The company received FDA clearance for ProFound Detection Version 4.0 for DBT on November 12, 2024, which demonstrated a 6.3% improved Area Under the ROC Curve (AUC) over the prior version. The first 3D tomosynthesis software clearance by the FDA was in 2018.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Being first is fleeting; others have since entered the market. The company has an installed base serving customers in over 50 countries.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The 'first' status is historical; current advantage relies on current performance, not past achievements. The latest version, ProFound Detection V4.0, shows performance improvements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e50%\u003c\/strong\u003e improvement for diagnosing cancer in women with dense breasts compared to the previous version.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e60%\u003c\/strong\u003e improvement in diagnosis of invasive lobular cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e38%\u003c\/strong\u003e improvement in detecting cancer smaller than 1 cm.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e21%\u003c\/strong\u003e improvement in identifying invasive breast cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The legacy perception helps sales, but the organization must constantly prove it is still the technological leader. The company's Annual Recurring Revenue (ARR) was $9.8 million as of Q4 2024 preliminary results, up from $8.7 million in Q4 2023. The company estimates reading more than 40 million mammograms worldwide in the last five years, with nearly 30% being tomosynthesis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It provides initial brand equity but does not guarantee future market share against newer, potentially better tech. The transition to a Software as a Service (SaaS) model is underway, with 19 cloud deals closed in Q4 2024.\u003c\/p\u003e\n\n\u003cp\u003eRecent Financial and Operational Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q4 2024 Preliminary\/Reported)\u003c\/td\u003e\n\u003ctd\u003eValue (Q4 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003eApproximately $5.1 to $5.3 million (Preliminary) or $5.4 million (Reported)\u003c\/td\u003e\n\u003ctd\u003e$4.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Recurring Revenue (ARR)\u003c\/td\u003e\n\u003ctd\u003eApproximately $9.8 million\u003c\/td\u003e\n\u003ctd\u003e$8.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin %\u003c\/td\u003e\n\u003ctd\u003e86%\u003c\/td\u003e\n\u003ctd\u003e91%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Deals Closed\u003c\/td\u003e\n\u003ctd\u003e106 (including 19 cloud deals)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 7. High Gross Profit Margin on SaaS\/Cloud Offerings\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The shift to cloud revenue drives margin expansion; Q1 2025 Gross Profit Margin reached \u003cstrong\u003e86%\u003c\/strong\u003e, up from \u003cstrong\u003e83%\u003c\/strong\u003e the prior year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately $4.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. High margins are common in pure software, but less so in integrated medical device software.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. Competitors are moving to cloud, but achieving that \u003cstrong\u003e86%\u003c\/strong\u003e margin requires efficient infrastructure and high utilization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Strong. The organization successfully managed the revenue recognition shift while improving the margin, showing operational control.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal ARR (Annual Recurring Revenue) was \u003cstrong\u003e$10.7 million\u003c\/strong\u003e in Q1 2025, up \u003cstrong\u003e18%\u003c\/strong\u003e year over year.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e19\u003c\/strong\u003e ProFound Cloud deals were closed in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eTotal operating expenses for Q1 2025 were \u003cstrong\u003e$5.3 million\u003c\/strong\u003e, a \u003cstrong\u003e4%\u003c\/strong\u003e decrease from Q1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained. Higher margins provide more capital for R\u0026amp;D and sales, creating a virtuous cycle that competitors with lower margins struggle to match.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 8. Integration into RadNet's DeepHealth Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Immediate access to RadNet’s installed base of over \u003cstrong\u003e1,500\u003c\/strong\u003e healthcare provider locations and integration with DeepHealth’s broader AI portfolio accelerates adoption and scale.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This is a unique, late-\u003cstrong\u003e2025\u003c\/strong\u003e resource resulting from the July \u003cstrong\u003e17, 2025\u003c\/strong\u003e, acquisition.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very High. No competitor can imitate this specific, immediate integration with a national imaging leader.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The entire organization is now aligned under a larger, well-capitalized entity focused on diagnostic imaging.\u003c\/p\u003e\n\n\u003cp\u003eThe integration brings specific financial and operational scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe transaction value was approximately \u003cstrong\u003e$103 million\u003c\/strong\u003e, based on RadNet's closing price on April 14, 2025.\u003c\/li\u003e\n\u003cli\u003eiCAD stockholders received \u003cstrong\u003e0.0677\u003c\/strong\u003e shares of RadNet common stock per iCAD share, representing approximately \u003cstrong\u003e$3.61\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eThe acquisition represented an approximately \u003cstrong\u003e98%\u003c\/strong\u003e premium to iCAD's closing stock price on April 14, 2025.\u003c\/li\u003e\n\u003cli\u003eiCAD contributed an additional \u003cstrong\u003e$19.6 million\u003c\/strong\u003e in annual revenue based on 2024 figures.\u003c\/li\u003e\n\u003cli\u003eiCAD's team of nearly \u003cstrong\u003e70\u003c\/strong\u003e employees is being integrated into DeepHealth.\u003c\/li\u003e\n\u003cli\u003eRadNet, inclusive of contracted radiologists, full-time, and per diem employees and technologists, has a total of over \u003cstrong\u003e11,000\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eiCAD (Pre-Acquisition Context)\u003c\/th\u003e\n\u003cth\u003eRadNet\/DeepHealth (Post-Integration Estimate)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Provider Locations\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e1,500\u003c\/strong\u003e across over \u003cstrong\u003e50\u003c\/strong\u003e countries.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,700\u003c\/strong\u003e sites in \u003cstrong\u003e50\u003c\/strong\u003e countries.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Mammograms Impacted by AI\u003c\/td\u003e\n\u003ctd\u003eFacilitating over \u003cstrong\u003e8 million\u003c\/strong\u003e annual mammograms.\u003c\/td\u003e\n\u003ctd\u003eCombined total of over \u003cstrong\u003e10 million\u003c\/strong\u003e annual mammograms impacted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransaction Value\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$103 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional Annual Revenue Contribution\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$19.6 million\u003c\/strong\u003e (2024 figures).\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This scale and synergy potential is the most significant advantage iCAD has gained this year, definitely changing its competitive profile.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiCAD, Inc. (ICAD) - VRIO Analysis: 9. Clinical Validation \u0026amp; Evidence Base\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Backed by clinical data showing ProFound AI Risk is \u003cstrong\u003e2.4X\u003c\/strong\u003e more accurate than traditional models for short-term risk. Detection AI increased cancer detection from \u003cstrong\u003e3.8 to 6.2\u003c\/strong\u003e per \u003cstrong\u003e1,000\u003c\/strong\u003e patients screened in one study.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Depth includes specific performance metrics like \u003cstrong\u003e92.5%\u003c\/strong\u003e expected AUC for Detection v4.0 and an active US customer base of \u003cstrong\u003e1,559\u003c\/strong\u003e facilities.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Research and development expenses for clinical testing were \u003cstrong\u003e$6.6 million\u003c\/strong\u003e for the year ended December 31, 2024. The algorithm is trained on data from over \u003cstrong\u003e100\u003c\/strong\u003e global locations, with iCAD estimating reading over \u003cstrong\u003e40 million\u003c\/strong\u003e mammograms worldwide in the last five years.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. Total Annual Recurring Revenue (ARR) reached \u003cstrong\u003e$10.7 million\u003c\/strong\u003e in Q1 2025. Full Year 2024 Revenue was \u003cstrong\u003e$19.61 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Clinical proof underpins adoption, with the company holding approximately \u003cstrong\u003e46%\u003c\/strong\u003e of the US AI market share among facilities using AI.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Clinical Performance Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePerformance Data\u003c\/td\u003e\n\u003ctd\u003eSource\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProFound AI Risk Accuracy vs. Traditional Models\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.4X\u003c\/strong\u003e more accurate\u003c\/td\u003e\n\u003ctd\u003eOne-to-two-year risk assessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Detection Rate Increase (Study)\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e3.8\u003c\/strong\u003e to \u003cstrong\u003e6.2\u003c\/strong\u003e per \u003cstrong\u003e1,000\u003c\/strong\u003e patients screened\u003c\/td\u003e\n\u003ctd\u003eAfter AI installation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFalse Interpretation Rate Drop (Study)\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e9.6%\u003c\/strong\u003e down to \u003cstrong\u003e7.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAfter AI installation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePositive Predictive Value Increase (Study)\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e29%\u003c\/strong\u003e to \u003cstrong\u003e57%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFor screenings where biopsies were performed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProFound Detection v4.0 Expected AUC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Specificity and Sensitivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecent Financial and Operational Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 Total Revenue: \u003cstrong\u003e$4.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Gross Profit Margin: \u003cstrong\u003e86%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 GAAP Net Loss: \u003cstrong\u003e($0.8) million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Position (Q1 2025): \u003cstrong\u003e$20.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 R\u0026amp;D Expenses: \u003cstrong\u003e$6.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Deals Closed in Q1 2025: \u003cstrong\u003e92\u003c\/strong\u003e, including \u003cstrong\u003e19\u003c\/strong\u003e ProFound Cloud implementations.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516184354965,"sku":"icad-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/icad-vrio-analysis.png?v=1740183197","url":"https:\/\/dcf-model.com\/pt\/products\/icad-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}